Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
|Articles|November 10, 2017
AJMC® in the Press, November 10, 2017
Author(s)AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Advertisement
A news article by The American Journal of Managed Care® was highlighted in Tuesday’s CER Daily Newsfeed from the National Pharmaceutical Council. The article, “
Advertisement
Related to this article
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Rosacea is likely missed, not rare, in skin of color, as low suspicion and hard-to-see redness delay diagnosis, said Hilary Baldwin, MD.
Hidradenitis suppurativa diagnosis often takes 7 to 10 years, and patients with skin of color often present with tunnels and scarring already in place.
In HIV, lymphoma survival tracks tumor stage and CD4 count, not viral suppression, a Spanish cohort shows.
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
3
New Mechanism of DME Treatment Highlights Clinical Trial Updates
4
Using Complement Inhibitors in GA Comes With Pros and Cons
5